CELU Celularity
- 3.2900
- +0.1700+5.45%
Celularity News
Celularity Inc. to Host Investor and Analyst Research & Development Day
FLORHAM PARK, N.J., April 22, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) ("Celularity"), a regenerative and cellular medicine company developing placental-derived allogeneic cell therapies and advanced
Celularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-K Filing
FLORHAM PARK, N.J., April 19, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) (the "Company"), a regenerative medicine company developing placental-derived allogeneic cell therapies and advanced biomaterial
Celularity Abstract "Emerging Technologies for the Management and Protection of Tendon Injuries: Decellularized Placental Biomaterials" Accepted at ORS Tendon Conference 2024
Celularity Inc. (Nasdaq: CELU) today announced that its abstract entitled "Emerging Technologies for the Management and Protection of Tendon Injuries: Decellularized Placental Biomaterials" was accepted by the Orthopedic Research Society (ORS) Tendon Conference, which will be held from May 30 - June 1, 2024 at the Mayo Clinic in Rochester, MN.
Celularity Announces Net Sales Trending Ahead of Expectations for First Quarter 2024; Implements Planned 2024 SG&A Reductions and Manufacturing Ramp for Advanced Biomaterial Products
Expects the First Quarter of 2024 will be the 4th consecutive quarter of both sequential and quarter-on-quarter net sales growth Implements plan to reduce 2024 selling, general & administrative expens
Celularity To Present Data Showing Senescent Cell Elimination By Off-The-Shelf Natural Killer Cells Derived From Human Placental Cells
Celularity Inc. (NASDAQ:CELU) ("Celularity"), a biotechnology company developing placental-derived allogeneic cell therapies and advanced biomaterial products, announced today that it will present in
Celularity Receives Healthcare Common Procedure Coding System Q Code Approval From The U.S. Centers For Medicare & Medicaid Services For Biovance 3L
Celularity Inc. (NASDAQ:CELU) ("Celularity"), a regenerative medicine company developing placental-derived allogeneic cell therapies and advanced biomaterial products, today announced that the U.S. Ce
Celularity Submits Request to U.S. FDA for Orphan Drug Designation for PDA-002 Asset Treating Facioscapulohumeral Muscular Dystrophy
FLORHAM PARK, N.J., March 20, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) ("Celularity"), a regenerative medicine company developing placental-derived allogeneic cell therapies and advanced biomaterial
Celularity CEO to Present on Cell Therapy's Potential to Improve Longevity at 2024 ABUNDANCE Summit
FLORHAM PARK, N.J., March 14, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) ("Celularity" or the "Company"), a biotechnology company developing placental-derived allogeneic cell therapies and biomaterial
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
GainersNuCana (NASDAQ:NCNA) shares moved upwards by 110.6% to $0.81 during Wednesday's pre-market session. The market value of their outstanding shares is at $42.7 million. Kintara Therapeutics (NASDA
Stock Market Resilience: Celularity Inc's (CELU) Remarkable Turnaround
During Tuesday's extended trading session, Celularity Inc. (NASDAQ: CELU) saw a notable uptick in its stock price, gaining 23.57 percent to $7.23 per share. In contrast to CELU's performance during the regular session, which saw a 15.30% loss and close at $5.89, the stock saw a rise in value as traders anticipated a noteworthy development. ...
Celularity CEO to Present Keynote Address at 2024 Society for Brain Mapping and Therapeutics Annual World Congress
FLORHAM PARK, N.J., March 12, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) ("Celularity" or the "Company"), a biotechnology company developing placental-derived allogeneic cell therapies and biomaterial
Celularity to Present Data Showing Cancer Tumor Reduction by Off-the-Shelf Cell Therapy Derived From Human Placental Cells
FLORHAM PARK, N.J., March 07, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) ("Celularity"), a biotechnology company developing placental-derived allogeneic cell therapies and biomaterial products, announced
Trading Halt: Halt Status Updated at 8:55:00 AM ET: Quotation Resumption: News and Resumption Times
Trading Halt: Halt Status Updated at 8:55:00 AM ET: Quotation Resumption: News and Resumption Times
There's No Escaping Celularity Inc.'s (NASDAQ:CELU) Muted Revenues Despite A 29% Share Price Rise
Celularity Inc. (NASDAQ:CELU) shares have continued their recent momentum with a 29% gain in the last month alone. Unfortunately, the gains of the last month did little to right the losses of the l
Celularity To Carry Out 1-for-10 Reverse Stock Split On February 29th, 2024
February 28th - $Celularity(CELU.US)$ is about to implement a 1-for-10 reverse stock split of shares. The shares will begin trading on a split-adjusted basis from February 29th, 2024.$Celularity(CELU.
Workday, Domino's And 3 Stocks To Watch Heading Into Monday
With U.S. stock futures trading lower this morning on Monday, some of the stocks that may grab investor focus today are as follows:
Stocks to Watch: Intuitive Machines, Celularity
By Ben Glickman Intuitive Machines revealed that its moon lander spacecraft had come down on its side. Chief Executive Stephen Altemus said at a press conference that the company believed the lander'
Celularity Approves Reverse Stock Split to Meet Nasdaq Rules
Celularity Announces 1-For-10 Reverse Stk Split
Celularity Announces 1-For-10 Reverse Stk Split
Celularity: Shares to Begin Trading on Reverse Split Adjusted Basis on Feb. 29 >CELU
Celularity: Shares to Begin Trading on Reverse Split Adjusted Basis on Feb. 29 >CELU
Analysis
Price Target
No Data
